Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SGLT2 inhibitor
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.- Tingting Ding, .et al. , J Diabetes Complications, 2024, Dec 9;39(2):108930 PMID: 39673870
- David Papadopoli, .et al. , Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Neil Tanday, .et al. , Biochem Pharmacol, 2020, Jul;177:114009 PMID: 32360307
- Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
- Marina Subramaniam, .et al. , Physiol Rep, 2019, May; 7(9): e14090 PMID: 31062524
- Angelopoulou A, .et al. , AAPS PharmSciTech, 2018, Feb;19(2):621-633 PMID: 8924948
-
SGLT1/SGLT2 inhibitor
Phlorizin is a competitive inhibitor of SGLT1 and SGLT2; this reduces renal glucose transport, lowering the amount of glucose in the blood.- Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
-
SGLT2 Inhibitor
Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).- Ming-Jer Hsieh, .et al. , Naunyn Schmiedebergs Arch Pharmacol, 2025, Apr 30 PMID: 40304747
- Courtney Sakolish, .et al. , Biomedicines, 2025, 13(3), 563
- Jing Zhou, .et al. , Exp Mol Med, 2022, Nov; 54(11): 2007-2021 PMID: 36385558
- David Papadopoli, .et al. , Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Angelopoulou A, .et al. , Nanomedicine, 2018, Oct;13(19):2435-2454 PMID: 30311542
-
SGLT2 inhibitor
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2. -
SGLT2 inhibitor
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. -
SGLT1/SGLT2 inhibitor
Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. -
SGLT2 Inhibitor
Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). -
SGLT2 inhibitor
Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. -
SGLT2 inhibitor
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. -
SGLT2 inhibitor
Canagliflozin hemihydrate is the hemihydrate form of canagliflozin, which is a SGLT2 inhibitor with IC50 of 2.2 nM for hSGLT2 in a cell-free assay, exhibits 413-fold selectivity over hSGLT1.- Wafaa N Albalawy, .et al. , Am J Physiol Renal Physiol, 2024, Jun 1;326(6):F1041-F1053 PMID: 38660713
-
SGLT2 inhibitor
Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. -
SGLT2 inhibitor
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2. -
SGLT inhibitor
Ertugliflozin pidolate belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus. -
SGLT2 inhibitor
Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor. -
SGLT inhibitor
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively. -
SGLT2 inhibitor
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. -
SGLT2 inhibitor
Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. -
SGLT1 inhibitor
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. -
HIV-1 Entry Inhibitor
Trilobatin is a natural sweetener extracted from Lithocarpus polystachyus Rehd, functioning primarily as an HIV-1 entry inhibitor by targeting the HIV-1 Gp41 envelope protein. It demonstrates neuroprotective effects and acts as a selective SGLT1/2 inhibitor, promoting the proliferation of human hepatoblastoma cells. Trilobatin is valuable for research involving HIV-1 entry mechanisms and potential therapeutic applications in hepatoblastoma and neuroprotection studies. -
Cytochrome P450 Inhibitor
Kushenol K is a flavonoid antioxidant derived from the roots of Sophora flavescens, functioning as a selective inhibitor of cytochrome P450 3A4 (CYP3A4) with a Ki value of 1.35 μM. This compound exhibits weak antiviral activity against herpes simplex virus type 2 (HSV-2) with an EC50 of 147 μM. Additionally, Kushenol K inhibits sodium-glucose co-transporters SGLT1 and SGLT2, making it relevant for research in metabolic disorders and viral infections. -
SGLT2 Inhibitor
WAY-123783 is a selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. It effectively enhances urinary glucose excretion while simultaneously lowering blood glucose levels in db/db mice, with an ED50 of 9.85 mg/kg. This compound is valuable for research in metabolic diseases, particularly diabetes, facilitating studies on glucose regulation and potential therapeutic interventions. -
SGLT2 Inhibitor
SGLT2-IN-1 is a selective inhibitor of the sodium-dependent glucose cotransporter SGLT2, exhibiting an IC50 of 33 nM in CHO cells transfected with human SGLT2. This compound demonstrates selectivity for SGLT2 over SGLT1, making it a valuable tool for research in glucose homeostasis and metabolic disorders. Additionally, SGLT2-IN-1 serves as an active metabolite of dapagliflozin, contributing to studies focused on diabetes and its associated complications. -
SGLT2 Inhibitor
Henagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 value of 2.38 nM for human SGLT2, exhibiting minimal activity against SGLT1 with an IC50 of 4324 nM. This compound is instrumental in diabetes research, facilitating studies on glucose homeostasis and potential therapeutic strategies for diabetic conditions. Its high selectivity and potency make it a valuable tool for investigating the physiological and pharmacological roles of SGLT2 in metabolic disorders. -
SGLT-2 Inhibitor
Enavogliflozin is a highly selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor that exhibits potent antidiabetic activity. By inhibiting SGLT-2, Enavogliflozin reduces glucose reabsorption in the kidneys, promoting increased glucose excretion in urine and thereby lowering blood glucose levels. This compound is primarily employed in research applications focused on diabetes management and cardiovascular health. -
SGLT-2 Inhibitor
Tianagliflozin is a selective inhibitor of sodium/glucose cotransporter 2 (SGLT-2), offering potential therapeutic benefit in the management of type 2 diabetes mellitus. By inhibiting SGLT-2, Tianagliflozin promotes the excretion of glucose through the kidneys, thereby lowering blood glucose levels. This compound is of interest in research focused on innovative treatments for glycemic control and metabolic regulation in diabetic patients. -
SGLT2 Inhibitor
Remogliflozin etabonate is a selective inhibitor of the sodium glucose cotransporter 2 (SGLT2), exhibiting Ki values of 1.95 μM for human SGLT2, 2.14 μM for rat SGLT2, 43.1 μM for human SGLT1, and 8.57 μM for rat SGLT1. As a prodrug derived from benzylpyrazole glucoside, it is metabolized into its active form, Remogliflozin, in vivo. This compound demonstrates significant antidiabetic activity in rodent models, making it a valuable tool for research into glucose regulation and diabetes therapies. -
SGLT2 Inhibitor
Sergliflozin etabonate is a potent and orally active sodium-glucose cotransporter 2 (SGLT2) inhibitor. It exhibits significant antidiabetic and antihyperglycemic effects, as evidenced by its ability to markedly reduce non-fasting blood glucose levels in diabetic mouse models. This compound is primarily utilized in diabetes research to explore therapeutic strategies for glucose management and metabolic regulation. -
SGLT1/SGLT2 Inhibitor
SGLT1/2-IN-1 is a dual inhibitor of SGLT1 and SGLT2, designed to effectively modulate glucose transport mechanisms. This compound exhibits significant biological activity in reducing glucose reabsorption in the kidneys and intestines, making it a valuable tool for research in diabetes and metabolic disorders. Its applications extend to investigating the role of sodium-glucose transporters in glucose homeostasis and potential therapeutic interventions for hyperglycemia. -
SGLT2 Inhibitor
Luseogliflozin hydrate is a selective and potent second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibiting an IC50 value of 2.26 nM. This compound is primarily utilized in research focused on type 2 diabetes mellitus (T2DM), where its ability to inhibit SGLT2 facilitates the reduction of glucose reabsorption in the kidneys, thereby lowering blood glucose levels. -
SGLT-2 Inhibitor
Rongliflozin is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2), which plays a crucial role in glucose reabsorption in the kidneys. This compound exhibits significant biological activity in the regulation of glucose metabolism and has potential applications in the treatment of type 2 diabetes mellitus (T2DM). Research with Rongliflozin can further elucidate its therapeutic effects and mechanisms of action in managing glycemic control. -
SGLT Inhibitor
rel-Licogliflozin is a sodium glucose cotransporter (SGLT) inhibitor, specifically targeting SGLT1 and SGLT2. This compound demonstrates significant biological activity in glucose transport modulation, making it valuable for research into diabetes and other metabolic disorders. Its role in disrupting glucose reabsorption in the kidneys has potential applications in developing therapeutic strategies for hyperglycemia management. -
SGLT-2 Inhibitor
Atigliflozin is a selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor, displaying IC50 values of 10 nM for hSGLT-2 and 8.2 μM for hSGLT-1. This compound is effective in lowering blood glucose levels and enhancing impaired oral glucose tolerance. Atigliflozin is utilized in research related to type II diabetes mellitus, contributing to the understanding of glucose regulation and potential therapeutic interventions. -
SGLT Inhibitor
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that exhibits significant antidiabetic activity. This compound effectively reduces renal glucose reabsorption, leading to increased glycosuria, which in turn lowers blood glucose and insulin levels. Velagliflozin proline is primarily utilized in research focused on diabetes management and related metabolic disorders. -
SGLT Inhibitor
SGLT1/2-IN-2 is a potent dual inhibitor targeting sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2), with IC50 values of 96 nM and 1.3 nM, respectively. This compound effectively regulates glucose absorption and reabsorption in the kidneys, making it a valuable tool in diabetes research. Its dual inhibitory action offers significant potential in studying glucose homeostasis and developing therapies for metabolic disorders. -
SGLT1/2 Inhibitor
SGLT1/2-IN-8 is a potent dual inhibitor of SGLT1 and SGLT2, exhibiting IC50 values of 4 nM and 1 nM, respectively. This compound demonstrates significant anti-hyperglycemic effects, making it a valuable tool for research in diabetes and glucose regulation. Its oral bioavailability supports its potential in in vivo studies aimed at exploring metabolic disorders. -
SGLT2 Inhibitor
BI-44847 is a selective and orally active inhibitor of the sodium-glucose cotransporter 2 (SGLT2), primarily targeting glucose reabsorption in the kidneys. This compound is known to enhance urinary glucose excretion (UGE) and reduce HbA1c levels, thus improving both fasting and postprandial glucose levels. BI-44847 is valuable for research applications focused on understanding and treating type 2 diabetes mellitus (T2DM). -
SGLT Inhibitor
YM-543 is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), designed to reduce hyperglycemia in type 2 diabetes models. It exhibits potent inhibition of both human and mouse SGLT2 activities at nanomolar concentrations, ultimately increasing urinary glucose excretion and improving glucose tolerance. When administered orally, YM-543 maintains its therapeutic effects for over 12 hours and enhances the action of other antidiabetic agents, such as rosiglitazone or metformin, without affecting blood glucose levels in non-diabetic models. This specificity underscores its potential utility in diabetic research and therapeutic strategies. -
SGLT1/2 Inhibitor
SAR-7226 is a dual inhibitor of sodium-glucose co-transporters SGLT1 and SGLT2. It demonstrates significant biological activity in reducing glucose reabsorption in the kidneys and intestines, making it a valuable tool for studying the mechanisms underlying type 2 diabetes. This compound is useful for research aimed at understanding the pharmacological modulation of glucose homeostasis and developing therapeutic strategies for managing diabetes and related metabolic disorders. -
SGLT1 Inhibitor
Mizagliflozin (sebacate) is a selective inhibitor of sodium-glucose cotransporter 1 (SGLT1), demonstrating significant potential in enhancing vascular cognitive impairment associated with small vessel disease. By inhibiting SGLT1 activity in neurons, Mizagliflozin (sebacate) effectively improves cerebral blood flow and cognitive functions such as spatial learning and memory in relevant mouse models. Additionally, Mizagliflozin (sebacate) has been shown to increase the survival rate of IL-1β-treated PC12HS cells, supporting its role in neuroprotection. This compound is valuable for research into therapeutic strategies for cognitive deficits linked to vascular health. -
SGLT2 Inhibitor
Velagliflozin proline hydrate is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that exhibits significant antidiabetic activity. By diminishing renal glucose reabsorption, Velagliflozin promotes glycosuria, effectively lowering blood glucose levels and insulin concentrations. This compound is primarily utilized in research focused on diabetes management and metabolic disorders. -
SGLT1/2 Inhibitor
Janagliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), exhibiting an IC50 of 0.0058 μM for SGLT2 and 4.802 μM for SGLT1. This compound functions primarily in the proximal renal tubules to inhibit glucose reabsorption, thereby enhancing urinary glucose excretion and lowering blood glucose levels. Janagliflozin holds potential for research applications targeting type 2 diabetes mellitus. -
SGLT2 Inhibitor
TA-1887 is a highly potent and selective SGLT2 inhibitor, exhibiting an IC50 of 1.4 nM. This compound demonstrates significant antihyperglycemic effects, making it valuable in the study of diabetes and glucose metabolism. Researchers can utilize TA-1887 to investigate the therapeutic potential and mechanisms of SGLT2 inhibition in metabolic disorders. -
SGLT2 Inhibitor
Dapagliflozin methyl acetate is a potent SGLT2 inhibitor, primarily targeting sodium-glucose co-transporter 2. It plays a crucial role in regulating glucose reabsorption in the kidneys, which is significant for managing blood glucose levels. This compound is commonly utilized in research related to type 2 diabetes and metabolic disorders, facilitating investigations into the pharmacological effects and potential therapeutic applications of SGLT2 inhibition.
